

HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) --- Annual/Unscheduled Follow-Up ---

SURVIVAL STATUS

Date of follow-up: ___/_/_/(*YYYY/MM/DD*) (if died: date of death, if lost to follow up: date last seen)

Survival status:

Alive

Dead

Lost to follow-up

Main cause of death:

(check only one main cause)

Relapse or progression/persistent disease	
Secondary malignancy	
CT-related	Select treatment related cause: (select all that apply) Graft versus Host Disease Non-infectious complication Infectious complication:
☐ HCT-related	(select all that apply)
GT-related	 Viral infection Fungal infection
IST-related	 Parasitic infection Infection with unknown pathogen
Other; specify:	
Autopsy performed:	
□ No	

- Yes
- Unknown

BEST RESPONSE Complete only for the first annual follow-up Not applicable for Inborn Errors
Best clinical/biological response after HCT* (observed before any subsequent treatment):
Date best response first observed: / _ / _ (YYY/MM/DD) Unknown
* Indicate the best clinical/biological response after HCT corresponding to indication diagnosis by selecting from the list provided in Appendix 1

EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry:	Treatment Type HCT Treatment Date/ _/ (YYYY/MM/DD)				
GRAFT FUNCTION					
 Poor graft function (defined as: frequent dependence on blood ar the absense of other explanations, such as disease relapse, drugs, No Yes: Date of poor graft function:// (YYYY/MN) Unknown Complete for every chimaerism test performed since last follow- 	or infection): 1/DD) 🔲 Unknown				
(complete only if patient received an allogeneic HCT) Chimaerism test date:// (YYYY/MM/DD) □ Unk	nown				
Source of cells tested: Peripheral blood					
Bone marrow					
Select cell type and complete relevant test results:					
Global:% donor 📋 Unknown					
Myeloid cells (i.e. CD33, CD15 or CD14):% donor	Jnknown				
T-cells (CD3):% donor Unknown B-cells (CD19 or CD20):% donor Unknown					
\square CD34+ cells:% donor \square Unknown					
☐ Other cell type; specify cells;% donor	Unknown				
copy and fill-in this table as many times as necessary.					
PREVENTIVE TH					
(Complete only if the patient rece					
Immunosuppression during this follow-up period: No Yes; Immunosuppresion stopped: No Yes; End date: Yes; Unknown	Unknown				
Letermovir used as CMV prophylaxis during this follow-up pe	riod:				
□ No					
☐ Yes; ☐ Started in this follow-up period; Start date:/	/(YYYY/MM/DD) 🔲 Unknown				
Ongoing since previous follow-up					
Letermovir treatment stop? No Yes; End date: Unknown	_//(<i>YYYY/MM/DD</i>) Unknown				
Unknown					

EBMT	EBMT Centre Identification Code (CIC): Treatment Type HCT Hospital Unique Patient Number (UPN): Treatment Date /(YYYY/MM/DD) Patient Number in EBMT Registry: Treatment Date /(YYYY/MM/DD)
Extended datase	et
	Antimicrobial prophylaxis
this follow-up r If yes, what ty	pe of prophylaxis? Antibacterial Antifungal Antiviral Antiphylaxis
	Antibacterial
Antibiotic (select all that w	vere administered)
Ciprofloxaci	n: Started in this follow-up period; Start date:/ _ / _ (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unkown
Levofloxacir	Started in this follow-up period; Start date://(YYYY/MM/DD) Unknown Ongoing since previous follow-up Unkown
Moxifloxacir	 Started in this follow-up period; Start date:/ _ / _ (YYYY/MM/DD) Ongoing since previous follow-up Unkown
Penicillin:	 Started in this follow-up period; Start date:/ _ / _ (YYYY/MM/DD) Ongoing since previous follow-up Unkown
	able antibiotic: Started in this follow-up period; Start date://(YYYY/MM/DD) Unknown Ongoing since previous follow-up Unkown ntibacterial prophylaxis was discontinued://(YYYY/MM/DD) Ongoing Unknown



Antimicrobial prophylaxis continued

Extended dataset				
Antiviral				
Did the patient receive CMV prophylaxis other than or in addition to letermovir during this follow-up period?				
Yes: Which drugs were use (select all that apply)	d? ☐ High-dose acyclovir ☐ High-dose valacyclovir			
Note: letermovir is not included as this is requested on the core	 Gancyclovir intravenous Valgancyclovir 			
dataset. Do not consider letermo for 'Other drug'.	☐ Foscarnet vir ☐ Other drug			
Final date CMV proph	ylaxis was discontinued: / _ / _ (YYYY/MM/DD) 🔲 Ongoing 🔲 Unknown			
or valacyclovir during this follow	xis for varicella-zoster virus (VZV) or herpes simplex virus (HSV) with either acyclovir w-up period? (Only for allo-HCT, not auto-HCT)			
Did the patient receive rituximab or another anti-CD20 monoclonal drug as prophylaxis for Epstein-Barr virus post-transplant lymphoproliferative disorder (EBV-PTLD) during this follow-up period? (Only for allo-HCT, not auto-HCT auto-HCT				
Yes				
Did the patient receive prophylaxis for hepatitis B virus (HBV) during this follow-up period?				
No Yes: Which drugs were us (select all that apply)	 Lamivudine Entecavir Tenofovir Other drug 			
Final date HBV proph	nylaxis was discontinued: / / (YYYY/MM/DD) 🔲 Ongoing 🔲 Unknown			



Antimicrobial prophylaxis

Extended dataset				
Antifungal				
Antifungal (select all that wer	re administered)			
Fluconazole:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up 			
Voriconazole:	 Unknown Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up 			
Posaconazole:	 Unknown Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown 			
ltraconazole:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown 			
Caspofungin:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown 			
🔲 Micafungin:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown 			
🗌 Anidulafungin:	 Started in this follow-up period; Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Unknown 			
Ambisome: ☐ (IV or inhalations)	 Started in this follow-up period; Start date:// (YYYY/MM/DD) □ Unknown Ongoing since previous follow-up Unknown 			
Final date antifu	ngal prophylaxis was discontinued: / _ / _ (YYYY/MM/DD) 🛛 Ongoing 🔲 Unknown			



Antimicrobial prophylaxis continued

	Antifungal
Did the patient receive prophylaxi	s for Pneumocystis jirovecii pneumonia (PJP) during this follow-up period?
🔲 No	
Yes: Which drugs were u	sed? 🔲 Trimethoprim-sulfamethoxazole
(select all that apply)	Dapsone
	Atovaquone
	Pentamidine inhaled
	Pentamidine intravenous
	Other drug
Final date prophylax	is was discontinued: / _ / (YYY/MM/DD) Ongoing Unknown

ЕВМТ	EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN):	Treatment Type 🔲 HCT
	Patient Number in EBMT Registry:	Treatment Date / _ / _ (YYYY/MM/DD)
Extended da	ataset	
	Pre-emptive	viral therapy
Did the patie this follow-u	ent receive pre-emptive therapy for a viral infection up period?	on during 🔲 No 🔄 Yes
-	, for what virus? CMV EBV t all that apply)	
	pre-emptive therapy for each CMV episode that o	
	eatment start date: I I (YYY/MM/DL	D) 🔲 Unknown
	al(s) used: all that apply)	
🔲 Valga	ancyclovir	
🔲 Ganc	cyclovir intravenous	
E Fosc	arnet	
Cidof	fovir	
🔲 Marit	pavir	
🔲 Spec	cific CMV T-cell	
🗌 Othe	r drug	
Was thi	is episode of CMV infection due to a resistant CM	IV strain?
🔲 No	Yes Unknown	
Copy as	often as necessary to reflect all episodes that occur	red
	pre-emptive therapy for each EBV episode that c	
EBV tre	eatment start date: / _ / _ / _ (YYYY/MM/DD)) 🔲 Unknown
	al(s) used: all that apply)	
	kimab	
	cific EBV T-cells	
	er drug	
Copy as	s often as necessary to reflect all episodes that occur	red

		Centre Identification Code (CIC Il Unique Patient Number (UPN			Treatment Typ	е 🔲 НСТ	
C		Number in EBMT Registry:			Treatment Dat	e / / (YYYY/MM/DD)	
	COMPLICATIONS SINCE THE LAST REPORT						
	GvHD Allogeneic HCT only						
Did gra	aft versus host	disease (GvHD) occur du	ring this follo	ow-up period	?		
	o (proceed to 'C	omplications since the last r	eport - Non-ir	fectious comp	olications')		
T Ye	Yes: Did the patient receive a systemic/immunosuppressive treatment for GvHD during this follow-up period?						
	No Yes: Started in this follow-up period; Date treatment started:// (YYYY/MM/DD) Unknown						
				alment Starte	a:/_		
		Ongoing since previous foll	ow-up				
	Ire	eatment stopped: 🗌 No	s: Stop date o	of treatment:	1	/(<i>YYYY/MM/DD</i>) 🔲 Unknown	
		Unl					
	Unknowi	ו					
Πυ	Inknown (procee	ed to 'Complications since th	e last report -	Non-infectiou	s complicatio	ons')	
					-		
Did a	cute Cy⊌D occi	ur during this follow-up pe	ariod2				
	0						
□ Ye	es: 🔲 Started i	n this follow-up period; Date	e of onset:	//	_ (YYYY/MM/L	DD) 🔲 Unknown	
	🗌 Ongoing	since previous follow-up					
	Maximum o	bserved organ severity sc	ore during <u>th</u>	<u>nis period</u> :			
[Skin:	□ 0 (none) □ 1	2	3	□ 4	🔲 Not evaluated 📋 Unknown	
	Liver:		2	3	4	☐ Not evaluated ☐ Unknown	
	Lower GI tract:		2	□ 3	4	 □ Not evaluated □ Unknown	
	Upper GI tract:	□ (none)			☐ Not evalu	ated 🗍 Unknown	

Lower GI tract:	$\Box 0 (none) \Box 1 \Box 2 \Box 3 \Box 4 \Box Not evaluated \Box Unknown$
Upper GI tract:	0 (none) 1 Not evaluated Unknown
Other site affected:	□ No □ Yes; specify:
Overall maximum g	grade observed: 1 2 3 4 Unknown Not evaluated
Steroid-refractory	acute GvHD: 🔲 No
	□ Yes: Started in this follow-up period; Date of onset: / _ / _ (YYYY/MM/DD) □ Unknown
	Ongoing since previous follow-up
	🗌 Unknown
aGvHD resolved:	
	Yes; Date of aGvHD resolution://(YYYY/MM/DD) Unknown
	Unknown
Inknown	



Treatment Type	🗌 нст

COMPLICATIONS SINCE THE LAST REPORT

-- GvHD --

Allogeneic HCT only

Extended dataset					
aGvHD first line treatment Did the patient receive steroids as first line treatment of aGvHD during This follow-up period? Steroid details during this follow-up period:					
 Prednisolone Methylprednisolone Other; specify: 	Started in this// follow-up period; Unknown Ongoing since previous follow-up	Unknown	No Yes:// Unknown Unknown		
 Prednisolone Methylprednisolone Other; specify: 	Started in this follow-up period; Unknown Ongoing since previous follow-up	Unknown	No Yes:// Unknown Unknown		
Copy and print this table as many times as needed, or enter the data directly into the EBMT Registry Were other systemic drugs/strategies used to treat aGvHD in the first line No Yes Unknown during this follow-up period: (other than steroids)					
f yes, select the drugs belo select all that apply)					
lame of drug/strategy					
] ECP] Ruxolitinib] MMF					
Cyclosporin A Tacrolimus					
Sirolimus Other; specify:					



Extended dataset

aGvHD first line treatment continued							
Steroid refractory definition covers other subtypes, such as dependent and intolerant, but 'Steroid Refractory' (SR) will be used as an umbrella term in this form Refractory: progression in any organ within 3, 4 or 5 days of therapy onset with >= 2 mg/Kg/day of prednisone equivalent, or failure to improve within 5 to 7 days of treatment initiation, or incomplete response after more than 28 days of immunosuppressive treatment including steroids. Dependent: Inability to taper prednisone under 2 mg/Kg/day after an initially successful treatment of at least 7 days or as the recurrence of aGVHD activity during steroid tapering.							
How did aGvHD respond to steroids during this follow-up period? (according to the definitions above) Steroid sensitive: No If steroid sensitive, please continue at 'Complications since the last report" Steroid refractory: No Yes: Unknown Steroid dependent: No Yes: Started in this follow-up period: Date of onset: / (YYYY/MM/DD) Ongoing since previous follow-up							
Steroid refractory/dependent aGvHD							
Did the patient receive treatmen during this follow-up period? (after steroid refractoriness/depend	follow-up period						
if SR/SD aGvHD treatment started Overall aGvHD grade at start of Organ(s) involved at start o	SR/SD GvHD treatment: 0 0 1 0 2 3 4 0 Not evaluated 0 Unknown						
Organ	Stage (Glucksberg scale)						
Skin	🗌 Stage 0 🔲 Stage 1 📄 Stage 2 📄 Stage 3 📄 Stage 4 📄 Not evaluated 🗋 Unknown						
Liver	🗌 Stage 0 🔲 Stage 1 📄 Stage 2 📄 Stage 3 📄 Stage 4 📄 Not evaluated 🗋 Unknown						
Lower GI tract	🗌 Stage 0 🔲 Stage 1 📄 Stage 2 📄 Stage 3 📄 Stage 4 📄 Not evaluated 🗋 Unknown						
Upper GI tract	🗌 Stage 0 🔲 Stage 1 🔲 Not evaluated 🔄 Unknown						



Treatment Type	нст

Extended dataset

Steroid refractory/dependent aGvHD continued

Drugs given in this line of treatment during this follow-up period

Line	of	treatment
------	----	-----------

Name of drug/ strategy (select all that applies)	Started / date (YYYY/MM/DD))	Stopped / date (YYYY/MM/DD)
	Started in this follow-up period;/ [Ongoing since previous follow-up	Unknown	 No Yes: / / □ Unknown □ Unknown
🔲 Ruxolitinib	Started in this follow-up period;/ [Ongoing since previous follow-up	Unknown	No Yes:// Unknown Unknown
	Started in this follow-up period;// [Ongoing since previous follow-up	Unknown	 □ No □ Yes:// □ Unknown □ Unknown
Cyclosporin A	Started in this follow-up period;/ [Ongoing since previous follow-up	_ Unknown	No Yes:// Unknown Unknown
Tacrolimus	Started in this follow-up period;// [Ongoing since previous follow-up	Unknown	No Yes:// Unknown Unknown
☐ Sirolimus	 Started in this follow-up period;// Ongoing since previous follow-up 	🗌 Unknown	No Yes: / / Unknown Unknown
Other; specify:	 Started in this follow-up period; / / / Ongoing since previous follow-up 	Unknown	No Yes: / / Unknown Unknown

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry



Treatment Type	🗌 нст
----------------	-------

Extended dataset

Steroid	refractory/dependent aGvHD
	continued

Organ involved during the course of treatment and response to the line of treatment during this follow-up period:

Organ involved during the course of treatment	Organ(s) involved during the course of treatment and Best response achieved	Date best response assessed (YYYY/MM/DD)
Skin	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Liver	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Lower GI tract	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Upper GI tract	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Overall (if organ specific is not available)	🗌 CR 🔲 PR 🔄 Progression 📄 Stable/no change 📄 Unknown	// Unknown

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry



	COMPLICATIONS	SINCE	THE LAST	REPORT	continued
--	---------------	-------	----------	--------	-----------

_ _

-- GvHD --

Allogeneic HCT only

Did chronic GvHD occur during this follow-up period?

🗌 No							
🗌 Yes: 🔲 Starte	ed in this follow-u	p period; D a	te of onset	:://	(YYYY/MI	M/DD) 🔲 Unknown	
Ongo	ing since previou	s follow-up				_	
	 Ongoing since previous follow-up Maximum NIH score during this period: Mild Moderate Severe Unknown Not evaluated Date of maximum NIH score:// (YYYY/MM/DD) Unknown 						
Maximur	n observed orga	n severity	score durir	ng <u>this period</u> :			
Skin:] 0 (none)	1	2	3	☐ Not evaluared	Unknown
Oral:	C] 0 (none)	□ 1	2	3	Not evaluated	Unknown
Gastroint	estinal:] 0 (none)	1	2	3	Not evaluated	Unknown
Eyes:] 0 (none)	□ 1	<u>□</u> 2	<u> </u>	Not evaluated	Unknown
Liver:	Ľ] 0 (none)	□ 1	2	3	Not evaluated	Unknown
Joints an	d fascia: 🛛 🗌] 0 (none)	1	2	3	Not evaluated	Unknown
Lungs:	E] 0 (none)	□ 1	2	3	Not evaluated	Unknown
Genitalia	: E] 0 (none)	□ 1	2	3	Not evaluated	🗌 Unknown
Other site	e affected:] No	Yes; spe	ecify:			
Steroid-refractory chronic GvHD: No Yes: Started in this Date of onset:// Unknown follow-up period; (YYYY/MM/DD)							
				joing since /ious follow-up			
cGvHD resolved: 🔲 No							
\square Yes; Date of cGvHD resolution: // (YYYY/MM/DD) \square Unknown							
	p syndrome obs both chronic and		D)) 🗌 Yes [] Unknown		

ЕВМТ	Hospital Uniqu	dentification Code (CIC): e Patient Number (UPN): r in EBMT Registry:		Treatment Type HCT _ Treatment Date/ _/ (YYYY/MM/DD)		
Extended data	set					
		cGvHD first line	treatment			
during this fo	llow-up perio	oids as first line treatment of cGvHD d? follow-up period:	🗌 No 📋 Yes	Unknown		
	of steroid	Treatment started / date (YYYY/MM/DD)	Initial dose (mg/kg/day)	Treatment stopped / date (YYYY/MM/DD)		
Prednisol	ednisolone	Started in this// follow-up period; Unknown Ongoing since previous follow-up	 Unknown	No Yes:// Unknown Unknown		
Prednisol	ednisolone	 Started in this// follow-up period;/ Unknown Ongoing since previous follow-up 	Unknown	No Yes: / / Unknown Unknown		
during this for If yes, select t (select all that Name of drug ECP Ruxolitinib MMF Cyclospori Tacrolimus	llow-up period he drugs belo apply) /strategy n A	/strategies used to treat cGvHD in the d: (other than steroids) ow:		No 🗌 Yes 🗌 Unknown		
Refractory: progr of prednisone for Dependent: inab- attempts, separat	definition covers ression of GvHD v 1-2 months. lity to control GVH ed by at least 8 w	vhile on prednisone at >= 1 mg/Kg/day for 1-2 wee ID symptoms while tapering prednisone below 0.2	tks or stable GvHD v 5 mg/Kg/day (or 0.5			
Steroid se If steroid sens Steroid ret	nsitive:	inue at 'Complications since the last report" No Yes Unknown No Yes: Started in this follow-up period; Ongoing since previous follow-u Unknown	Date of onset	t:// □ Unknown		
		Yes: Started in this follow-up period; Ongoing since previous follow-u Unknown		:// 🔲 Unknown)		

ЕВМТ	EBMT Centre lo Hospital Unique Patient Number	e Patient Nur	mber (UPN):			atment Type HC1	T _/ (YYYY/MM/DD))
Extended data	set							
		Ste	roid refracto	ory/depende	ent/intolera	nt cGvHD		
Did the pa follow-up	tient receive tro period?	eatment fo	r SR/SD/SI cG	SvHD during	this 🗌 No		ed in this □ U v-up period	nknown
(after stero	id refractoriness	/dependend	ce/intolerance	was establis	hed)		oing since	
if SR/SD/SI	cGvHD treatmei	nt started in	this follow-up	period:		previo	ous follow-up	
Overall cGv	HD grade at sta	art of SR/SI	D/SI GvHD tre	eatment: 🕅	Mild 🔲 Mode	erate 🔲 Severe 🗌 N	Vot evaluated 🔲 U	Inknown
Organ(s)	involved at sta	rt of SR/SD)/SI GvHD trea	atment:	_			
Skin:] 0 (none)	1	2	3	□ Not evaluared	Unknown	
Oral:	Γ] 0 (none)	1	2	3	Not evaluated	🔲 Unknown	
Gastrointe	estinal:] 0 (none)	1	2	3	□ Not evaluated	Unknown	
Eyes:	Γ] 0 (none)	1	2	3	Not evaluated	Unknown	1
Liver:	Γ] 0 (none)	1	2	3	Not evaluated	🔲 Unknown	
Joints and	l fascia: 🛛 🗌] 0 (none)	1	2	3	☐ Not evaluated	Unknown	
Lungs:] 0 (none)	<u> </u>	2	3	Not evaluated	🔲 Unknown	
Genitalia:	Γ] 0 (none)	1	2	3	☐ Not evaluated	Unknown	
Other site	affected:] No	Yes; spec	cify:				

J



Treatment Type

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Extended dataset

Steroid refractory/dependent/intolerant cGvHD

Drugs given in this line of treatment during this follow-up period

Line of treatment ____

Name of drug/ strategy (select all that applies)	Started / date (YYYY/MM/DD)		Stopped / date (YYYY/MM/DD)
	Started in this follow-up period; / / /		□ No
	Ongoing since		□ Yes:// □ Unknown
	previous follow-up		Unknown
Ruxolitinib	Started in this follow-up period;		□ No
	Ongoing since		Yes:// Unknown
	previous follow-up		
MMF/CellCept	Started in this follow-up period;//	🔲 Unknown	□ No
	Ongoing since previous follow-up		☐ Yes:// ☐ Unknown
	Started in this		Unknown No
🔲 Belumosudil	follow-up period;//	Unknown	□ Yes:// □ Unknown
	Ongoing since previous follow-up		
	Started in this follow-up period;//	🔲 Unknown	No
🔲 Ibrutinib	Ongoing since		Yes:// Unknown
	previous follow-up Started in this		
Everolimus	└┘ follow-up period;//	🔲 Unknown	
	Ongoing since previous follow-up		Yes:// Unknown
Sirolimus	Started in this follow-up period; / / /	🔲 Unknown	
	Ongoing since previous follow-up		□ ^{Yes:} // □ Unknown
	Started in this		
Cyclosporin A	└─ follow-up period; / / /	Unknown	□ Yes:// Unknown
	Ongoing since previous follow-up		
	Started in this follow-up period; / _ / / / / / / / / _ / / _ / _ / / _ / / _ / / _ / / _ / _ / _ / _ / _ / _ / _ / _ / _ / _ / / _ / _ / / _ / _ / / _ / _ / / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / _ / / / _ / / / _ / / / _ / / / _ / / / _ / / / _ / / / _ / / / / _ / / / _ / / / / _ /	🔲 Unknown	□ No
Tacrolimus	Ongoing since		□ Yes:// □ Unknown
	previous follow-up		Unknown
Other; specify:	Started in this follow-up period; $ / - / - /$	🗌 Unknown	No
	Ongoing since	_	Yes:// Unknown Unknown
	└── previous follow-up		

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry



Steroid refractory/dependent/intolerant cGvHD

Extended dataset

Organ involved during the course of treatment and response to the line of treatment during this follow-up period:

Organ involved during the course of treatment	Organ(s) involved during the course of treatment and Best response achieved	Date best response assessed (YYYY/MM/DD)
Skin	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Oral	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Gastrointestinal	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Eyes	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Liver	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Joints and fascia	No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown	// Unknown
Lungs	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Genitalia	 No Yes: CR PR Progression Stable/no change Unknown Not evaluated Unknown 	// Unknown
Overall (if organ specific is not available)	🗌 CR 🔄 PR 🔄 Progression 🗌 Stable/no change 🗌 Unknown	// Unknown

If there were more lines of treatment, copy the page as often as necessary or enter the data directly into the EBMT Registry

EBMT

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

	COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications			
	• 			
	 Did non-infectious complications occur during the follow-up period? (Please only report toxic events here that are above Grade 2 and not linked to GvHD and/or infections) No (proceed to 'Complications since the last report - Infectious complications') Yes (report in the table below) Unknown 			
Se	condary graft failure			
Со	mplication observed during this follow-up period? 🔲 No			
	☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment ☐ Unknown			
Ма	iximum grade observed during <u>this period</u> : 🔲 Non-fatal 🛛 🗌 Fatal			
0	nset date (YYYY/MM/DD):/ / Unknown Only if newly developed			
R	esolved: 🔲 No			
	☐ Yes; Stop date (<i>YYY/MM/DD):</i> / _ / _ ☐ Unknown ☐ Unknown			
Са	rdiac event			
	mplication observed during this follow-up period? No*			
	Yes: Newly developed Ongoing since previous assessment			
Ma	aximum CTCAE grade observed during <u>this period</u> : 3 4 5 (fatal) Unknown			
	set date (YYYY/MM/DD): / _ / _ / Unknown Only if newly developed solved: No			
	☐ Yes; Stop date (YYYY/MM/DD): / _ / ☐ Unknown			
	ntral nervous system (CNS) toxicity			
Co	mplication observed during this follow-up period?			
N/-	tximum CTCAE grade observed during <u>this period</u> : 3 4 5 (fatal) Unknown			
	set date (YYYY/MM/DD): / _ / _ Unknown Only if newly developed solved: No			
ne				
	Yes; Stop date (YYYY/MM/DD):/ Unknown Unknown			
Ga	strointestinal (GI) Toxicity (non-GvHD and non-infectious related)			
Со	mplication observed during this follow-up period? 🔲 No*			
	Yes: Newly developed Ongoing since previous assessment			
Ma	ximum CTCAE grade observed during <u>this period</u> : 3 4 5 (fatal) Unknown			
On	set date (YYYY/MM/DD):// Unknown Only if newly developed			
Re	solved: No Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown			

(EBMT	

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ _ / _ _ (YYYY/MM/DD)

٦

	COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications		
Liv	er disorder		
	mplication observed during this follow-up period? No*		
	☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment		
Ма	ximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown		
	set date (YYYY/MM/DD): / _ / Unknown Only if newly developed		
Re	solved: 🔲 No		
	Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown		
Re	nal failure (chronic kidney disease, acute kidney injury)		
Со	mplication observed during this follow-up period? 🔲 No*		
	Yes: Newly developed Ongoing since previous assessment		
	ximum CTCAE grade observed during <u>this period</u> : 3 4 5 (fatal) Unknown		
	set date (YYYY/MM/DD):/ Unknown Only if newly developed		
Re			
	Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown		
	spiratory disorders		
Со	mplication observed during this follow-up period? 🔲 No*		
	Yes: Newly developed Ongoing since previous assessment Unknown		
Ма	ximum CTCAE grade observed during <u>this period</u> : 3 4 5 (fatal) Unknown		
	set date (YYYY/MM/DD): / _ / Unknown Only if newly developed		
	solved: No		
	□ Unknown		
Sk	n Toxicity (non-GvHD and non-infectious related)		
Complication observed during this follow-up period? No*			
	☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessment		
Ма	ximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown		
	Onset date (YYYY/MM/DD): / _ / _ Unknown Only if newly developed		
Re	solved: 🔲 No		
	Yes; Stop date (YYYY/MM/DD):/ Unknown		
	Unknown		

* Grade 0-2

(EBMT	
	-	

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ _ / _ _ (YYYY/MM/DD)

COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications			
Vascular event			
Complication observed during this follow-up period?	 No* Yes: Newly developed Ongoing since previous assessment Unknown 		
Maximum CTCAE grade observed during this period:	3 4 5 (fatal) Unknown		
Onset date (YYYY/MM/DD):/ Unl Resolved: No	known Only if newly developed		
Yes; Stop date (YYYY/MM/DD):	/ / Unknown		
Unknown			
Avascular necrosis (AVN)			
Complication observed during this follow-up period?	□ No*		
	 Yes: Newly developed Ongoing since previous assessment Unknown 		
Maximum CTCAE grade observed during this period:	3 4 5 (fatal) Unknown		
Onset date (YYYY/MM/DD): / _ / Uni Resolved: _ No	known Only if newly developed		
<pre>Yes; Stop date (YYYY/MM/DD):</pre>	//_ Duknown		
Cerebral haemorrhage			
Complication observed during this follow-up period?	□ No*		
	 Yes: Newly developed Ongoing since previous assessment Unknown 		
Maximum CTCAE grade observed during this period:	3 4 5 (fatal) Unknown		
Onset date (YYYY/MM/DD):/ Uni Resolved:No	known Only if newly developed		
Yes; Stop date (YYYY/MM/DD):	/ / Unknown		
Haemorrhage (other than cerebral haemorrhage)			
Complication observed during this follow-up period?	□ No*		
	 Yes: Newly developed Ongoing since previous assessment Unknown 		
Maximum CTCAE grade observed during this period:	3 4 5 (fatal) Unknown		
Onset date (<i>YYYY/MM/DD</i>): / _ / _ Unknown Only if newly developed Resolved: No			
<pre>Yes; Stop date (YYYY/MM/DD):</pre>	//_ Duknown		

(EBN	ΛL

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ _ / _ _ (YYYY/MM/DD)

COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications			
Cerebral thrombosis			
Complication observed during this follow-up period?			
Yes: Newly developed Ongoing since previous assessmer			
Maximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown			
Onset date (YYYY/MM/DD): / _ / Unknown Only if newly developed Resolved: No			
Yes; Stop date (YYYY/MM/DD): / _ Unknown			
Cytokine release syndrome (CRS)			
Complication observed during this follow-up period? 🔲 No*			
🗌 Yes: 🔲 Newly developed 🔲 Ongoing since previous assessmer 🗌 Unknown			
Maximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown			
Onset date (YYYY/MM/DD): / _ / Unknown Only if newly developed Resolved: No			
Yes; Stop date (YYYY/MM/DD):/ Unknown Unknown			
Haemophagocytic lymphohistiocytosis (HLH)			
Complication observed during this follow-up period? 🔲 No*			
🗌 Yes: 🔲 Newly developed 🔲 Ongoing since previous assessmer			
Maximum CTCAE grade observed during this period: 3 4 5 (fatal) Unknown			
Onset date (YYYY/MM/DD): / _ / Unknown Only if newly developed Resolved: No			
<pre>Yes; Stop date (YYYY/MM/DD): / _ Unknown Unknown</pre>			
Pure red cell aplasia (PRCA)			
Complication observed during this follow-up period? No			
☐ Yes: ☐ Newly developed ☐ Ongoing since previous assessmer ☐ Unknown			
Maximum grade observed during this period: 🗍 Non-fatal 👘 Fatal			
Onset date (YYYY/MM/DD): / _ / Unknown Only if newly developed			
Resolved: No			
Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown			

* Grade 0-2

EBMT Ho	ospital Unique Patient Number (UPN):	atment Type HCT			
	COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications				
Destaviav versible	encentral another considering (DDEC)				
	encephalopathy syndrome (PRES)				
Complication obser	ved during this follow-up period?	eloped 🔲 Ongoing since previous assessment			
Maximum grade obs	served during <u>this period</u> : 🗌 Non-severe 🗌 Severe 🛛	🗌 Fatal 🛛 🔲 Unknown			
	IM/DD): / _ / Unknown Only if newly d				
Yes;	Stop date (YYYY/MM/DD):// Unknov	vn			
Unkn	own				
Transplant-associat	ed microangiopathy (TMA)				
Complication obser	rved during this follow-up period? 🔲 No*				
		eloped Ongoing since previous assessment			
Maximum avada ak					
Maximum grade ob	served during this period: Non-severe Severe	Unknown			
Onset date (YYYY/// Resolved: No	/IM/DD): / _ / Unknown Only if newly de	eveloped			
☐ Yes;	Stop date (YYYY/MM/DD):/ Unknow	/n			
🗌 Unkn	lown				
Extended dataset					
Was TA-TMA tre	atment given during this follow-up period: 🛛 🗌 No	🗌 Yes 📄 Unknown			
TA-TMA treatme	nt given during this follow-up period				
Line of tre	atment				
Name of drug	Start date (YYYY/MM/DD)	Stopped / date (YYYY/MM/DD)			
Defibrotide	Started in this follow-up period; $____'_='=='$ Unknown	□ No □ Yes:// Unknown			
	Ongoing since previous follow-up				
Eculizumab	Started in this follow-up period; $__\/\/\$ Unknown	□ No □ Yes:// □ Unknown			
	Ongoing since previous follow-up				
Narsoplimab	Started in this follow-up period;/ Unknown				
	Ongoing since previous follow-up				



COMPLICATIONS SINCE THE LAST REPORT

-- Non-infectious complications --

Extended dataset

Name of drug	Start date (YYYY/MM/DD)	Stopped / date (YYYY/MM/DD)	
	Started in this follow-up period; $//$ Unknown		
Pegcetacoplan	Ongoing since previous follow-up	Yes:// Unknown Unknown	
🔲 Iptacopan	Started in this follow-up period;// Unknown Ongoing since	□ No □ Yes: / / □ Unknown	
	└┘ previous follow-up		
🗖 Danicopan	Started in this follow-up period; $^{\prime}^{\prime}$ Unknown		
	Ongoing since previous follow-up	Yes:// Unknown Unknown	
Ravulizumab	Started in this follow-up period;/ / Unknown		
	Ongoing since previous follow-up	Yes:// Unknown Unknown	
Other; specify:	Started in this follow-up period; $____/__/__/__$ Unknown		
	Ongoing since previous follow-up	Yes:// Unknown Unknown	
Other TA-TMA treatment given in this line of treatment during this follow-up period:			
Renal replacement therapy performed: No Yes: Started in this			

	Started in this Yes: Started in this follow-up period;/ Unknown Ongoing since previous follow-up			
Mechanical ventilation performed:	Unknown No Started in this			
	$\Box \text{ Yes:} \Box \text{ follow-up period; } ___/_/\ \Box \text{ Unknown}$			
	Ongoing since			
	☐ previous follow-up ☐ Unknown			
Exchange plasmapheresis performed:	 No Yes: ☐ follow-up period;// ☐ Unknown Ongoing since previous follow-up 			
Response to this line of TA-TMA treatment during this follow-up period				
Did the patient achieve complete response?] No 🔄 Yes 🔄 Unknown			
Defined as normal LDH, no organ manifestations, high-risk TA-TMA harmonisation criteria not fulfilled anymore				
If yes, date of complete response: / _ / Unknown				
If no, did the patient achieve partial response? 🔲 No 🛛 Yes 🔄 Unknown				
Defined as LDH decreased, residual organ manifestations, high-risk TA-TMA harmonisation criteria not fulfilled anymore				
If yes, date of partial response:	/_/ Unknown			

Copy and print this table as many times as needed, or enter the data directly into the EBMT Registry



Treatment Date _ _ _ / _ / _ (YYY//MM/DD)

COMPLICATIONS SINCE THE LAST REPORT Non-infectious complications					
eno-occlusive disease (VOD)					
aximum grade observed during	ng <u>this period</u> :	☐ Yes: ☐ Newly develop ☐ Unknown	bed Dongoing since previous assessment Very severe D Fatal D Unknowr loped		
☐ Yes; Stop date ☐ Unknown	(YYYY/MM/DD): _	// Unknown			
VOD treatment given during	Extended dataset VOD treatment given during this follow-up period: VOD treatment given during this follow-up period				
Line of treatment	1				
Name of drug		date (YYYY/MM/DD)	Stopped / date (YYYY/MM/DD)		
Defibrotide	Started in this follow-up perio Ongoing since previous follow	d; / / 🔲 Unknown /-up	 No Yes: / / □ Unknown □ Unknown 		
Started in this			 □ No □ Yes:// □ Unknown □ Unknown 		
			;/ Unknown		
		No Started in this Yes: ☐ follow-up period; ☐ Ongoing since ☐ previous follow-u ☐ Unknown	;// Unknown		
Extracoporeal membrane oxygenation performed:		 No Started in this follow-up period;// Unknown Ongoing since previous follow-up Unknown 			
Defined as serum bilirubin <2 replacement therapy If yes, date of complete	plete response? mg/dL, no oxygen e response:	g this follow-up period No Yes Unknown support, eGFR >50% from baseline III Unknown ponse? No Yes Unkr			
If yes, date of par	tial response:	• • • •	or eGFR ≤50% from baseline before VOD		



COMPLICATIONS SINCE THE LAST REPORT
Non-infectious complications

Other complication observed during this follow-up period? Ves: Newly developed Ongoing since previous assessment Unknown	
Specify: Consult appendix 4 for a list of complications that should not be reported (Indicate CTCAE term)	
Maximum CTCAE grade observed 3 4 5 (fatal) Unknown	
Onset date (YYYY/MM/DD):/ Unknown Only if newly developed	
Resolved: No Yes; Stop date (YYYY/MM/DD): / _ / _ Unknown Unknown	

If more other complications occurred, copy and fill-in this table as many times as necessary.

* Grade 0-2



EBMT Centre Identification Code (CIC):	Treatment Type	🗌 нст	
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT Registry:	Treatment Date	//	(YYYY/MM/DD)

Extended dataset

Additional late complications

Indicate if any of the	following complications occurred during follow-up period:
Cataract diagnosis:	
	Yes; Date first reported:// Unknown
	Did the patient undergo cataract surgery? No Yes Unknown
	Date of cataract operation: / / Unknown
Thyroid disorder	□ No
requiring treatment:	Yes; Type of thyroid disorder: Hyperthyroidism
	Hypothyroidism
	Other; specify:
	Start date of treatment: / _ / _ Unknown
Osteoporosis	
requiring treatment:	Yes; Start date of treatment:// Unknown
Bone fracture:	No
	Yes; Bone involved:
	Date of fracture: / _ / Unknown
Iron overload	
requiring treatment:	Yes; Start date of treatment:// Unknown
	Unknown
Dyslipidemia	□ No
requiring treatment:	Yes; Start date of treatment:/ Unknown Unknown
Arterial hypertension	
requiring treatment:	Yes; Start date of treatment:// Unknown
Morbid obesity	
requiring treatment:	Yes; Start date of treatment:/ Unknown
Mental health disorder	□ Unknown r □ No
requiring treatment:	Yes; Diagnosis:
	Start date of treatment:/ Unknown
Cognitive function dis	
requiring treatment:	☐ No ☐ Yes; Diagnosis:
	Start date of treatment: / _ / _ Unknown
Return to work/school	I: NO
	Yes; Involvement: Parttime
	Fulltime
	Unknown
	Date of return to work/school: / _ / Unknown
	Unknown

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Infectious complications
Do not report infections that were already reported as resolved on the previous assessment and did not reoccur. Did infectious complications occur during the follow-up period? No Consult appendix 4 for a list of complications that should not be reported Yes (report all infection-related complications below) Unknown
Bacterial infection: No Yes Unknown 1) New or ongoing: Newly developed Ongoing since previous assessment Start date: //(YYY/MM/DD) only if newly developed Unknown Gram-positive Gram-negative Other Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs of disease
Administration of pathogen-directed therapy
Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: No Yes; specify***: Unknown
Resolved: 🗌 No 📄 Yes 📄 Unknown
(if patient died) Contributory cause of death: 🗌 No 📄 Yes 📄 Unknown
 2) New or ongoing: Newly developed Ongoing since previous assessment Start date:/ _ / _ (YYYY/MM/DD) only if newly developed Unknown Gram-positive Gram-negative Other Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs of disease
Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: Intravascular Catheter-related
Unknown Resolved: No Yes Unknown (if patient died) Contributory cause of death: No Yes Unknown
If more than 2 bacterial infections, copy and fill-in this table as many times as necessary.
* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2
 ** Indicate CTCAE term by choosing from the list provided in Appendix 3
 *** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5

(EB	MT
	_	

COMPLICATIONS SINCE THE LAST REPORT Infectious complications continued
Viral infection: 🔲 No 🔄 Yes 🔄 Unknown
1) New or ongoing: 🔲 Newly developed 🗌 Ongoing since previous assessment
Start date :// (YYYY/MM/DD) only if newly developed Unknown Pathogen *:
If the pathogen was CMV/EBV: Was this infection a reactivation?
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs of disease
Administration of pathogen-directed therapy
Unknown
Indicate at least 1 location involved during this period:
Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: 🔲 No 🔄 Yes 🔄 Unknown
(if patient died) Contributory cause of death: No Yes Unknown
2) New or ongoing: 🔲 Newly developed 🗌 Ongoing since previous assessment
Start date: / _ / (YYYY/MM/DD) only if newly developed Unknown
Pathogen*:
If the pathogen was CMV/EBV: Was this infection a reactivation?
Infection with clinical implications: 🗌 No
\Box Yes: (select all that apply during this period)
Symptoms/signs of disease
Administration of pathogen-directed therapy
Unknown
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: 🗌 No 🔄 Yes 📄 Unknown
(if patient died) Contributory cause of death: 🔲 No 🛛 Yes 📄 Unknown
If more than 2 viral infections, copy and fill-in this table as many times as necessary.

* Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2 ** Indicate CTCAE term by choosing from the list provided in Appendix 3

*** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5



COMPLICATIONS SINCE THE LAST REPORT Infectious complications continued
Fungal infection: No Yes Unknown
 New or ongoing: Newly developed Ongoing since previous assessment Start date:// (YYYY/MM/DD) only if newly developed Unknown Yeasts Moulds Pathogen*:
Infection with clinical implications: \Box No \Box Yes: (select all that apply during this period)
Symptoms/signs of disease
Administration of pathogen-directed therapy Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: No Yes; specify***: Unknown Resolved: No Yes Unknown (if patient died)
Contributory cause of death: No Yes Unknown 2) New or ongoing: Newly developed Ongoing since previous assessment
Start date:// (YYYY/MM/DD) only if newly developed Unknown Yeasts Moulds Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs or disease
Administration of pathogen-directed therapy
Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**: Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Intravascular catheter-related infection: No Ves; specify***: Unknown
Resolved: No Yes Unknown
(if patient died) Contributory cause of death: No Yes Unknown
If more than 2 fungal infections, copy and fill-in this table as many times as necessary. Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2

^{**} Indicate CTCAE term by choosing from the list provided in Appendix 3 *** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5

(EB	MT

Parasitic infection: No Yes Unknown 1) New or ongoing: Newly developed Ongoing since previous assessment Start date: //(YYY/MM/DD) only if newly developed Unknown Protozoa Helminths Pathogen*:
Start date: //(YYYY//MM/DD) only if newly developed Unknown Protozoa Helminths Pathogen*:
 Protozoa Helminths Pathogen*: Infection with clinical implications: No Yes: (select all that apply during this period) Symptoms/signs or disease
Yes: (select all that apply during this period)
Administration of pathogen-directed therapy
Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: No Yes Unknown (if patient died) Contributory cause of death: No Yes Unknown 2) New or ongoing: Newly developedOngoing since previous assessment Start date:/(YYYY/MM/DD) only if newly developedUnknown
Protozoa Helminths Pathogen*:
Infection with clinical implications: No Yes: (select all that apply during this period)
Administration of pathogen-directed therapy
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)**:
Localisation 2 (CTCAE term)**:
Localisation 3 (CTCAE term)**:
Resolved: No Yes Unknown (if patient died) Contributory cause of death: No Yes Unknown
If more than 2 parasitic infections, copy and fill-in this table as many times as necessary. * Indicate the pathogen and sub-type (if applicable) by choosing from the list of pathogens provided in Appendix 2 ** Indicate CTCAE term by choosing from the list provided in Appendix 3

*** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5



EBMT Centre Identification Code (CIC): ____ Hospital Unique Patient Number (UPN): _____ Patient Number in EBMT Registry: _____ Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Localisation 1 (CTCAE term)*: Localisation 2 (CTCAE term)*: Localisation 3 (CTCAE term)*: Intravascular catheter-related infection: No Yes; specify**: Unknown	Unknown g this period) sease
Start date: / _ / _ (YYYY/MM/DD) only if newly developed Infection with clinical implications: No Yes: (select all that apply during Symptoms/signs or dis Administration of pather Unknown ndicate at least 1 location involved during this period: Localisation 1 (CTCAE term)*: Localisation 2 (CTCAE term)*: Localisation 3 (CTCAE term)*: Intravascular catheter-related infection: No Yes; specify**: Unknown	Unknown g this period) sease
Yes: (select all that apply during Symptoms/signs or dis Administration of pathe Unknown Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)*: Localisation 2 (CTCAE term)*: Localisation 3 (CTCAE term)*: Intravascular catheter-related infection: Yes; specify**: Unknown	sease
Unknown Undicate at least 1 location involved during this period: Localisation 1 (CTCAE term)*: Localisation 2 (CTCAE term)*: Localisation 3 (CTCAE term)*: Intravascular catheter-related infection: Yes; specify**: Unknown	ogen-directed therapy
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)*: Localisation 2 (CTCAE term)*: Localisation 3 (CTCAE term)*: Intravascular catheter-related infection: No Yes; specify**: Unknown	
Localisation 2 (CTCAE term)*: Localisation 3 (CTCAE term)*: Intravascular catheter-related infection: DNO Yes; specify**: Unknown	
Intravascular catheter-related infection: No	
☐ Yes; specify**: ☐ Unknown	
Resolved: No Yes Unknown (<i>if patient died</i>)	
2) New or ongoing: Newly developed Dongoing since previous a	ssessment
Start date://(YYY/MM/DD) only if newly developed	Unknown
Infection with clinical implications: No	g this period)
 ☐ Symptoms/signs or dis	ease
☐ Administration of patho ☐ Unknown	gen-directed therapy
Indicate at least 1 location involved during this period: Localisation 1 (CTCAE term)*:	
Localisation 2 (CTCAE term)*:	
Localisation 3 (CTCAE term)*:	
Intravascular catheter-related infection: 🗌 No	
☐ Yes; specify**:	
Resolved: No Yes Unknown (<i>if patient died</i>)	

* Indicate CTCAE term by choosing from the list provided in Appendix 3

** If intravascular catheter-related infection, specify it by choosing from the list provided in Appendix 5

ЕВМТ	EBMT Centre Identification Code (CIC Hospital Unique Patient Number (UPN	
	Patient Number in EBMT Registry:	
Extended data	iset	
	SARS	-CoV-2 RELATED QUESTION
Did the pation	ent receive a vaccination against s	SARS-CoV-2 during this follow-up period?
Yes:	Number of doses:	Unknown
	Date of the last dose:	//(YYYY/MM/DD) 🔲 Unknown
🔲 Unknowr	n	
	SECONDARY MALIC	GNANCIES AND AUTOIMMUNE DISORDERS
Did seconda	ary malignancy or autoimmune dis	sorder occur since the last follow-up?
	s this disease an indication for a s	ubsequent HCT/CT/IST/GT?
	No (complete the non-indication diag	-
	Yes (complete the relevant indication	a diagnosis form)
Unknown	1	
	A	DDITIONAL TREATMENTS
Did the pat	ient receive any additional diseas	e treatment since the last follow-up?
No		
🗌 Yes; 🗌] Started in this follow-up period;	complete the "Treatment — non-HCT/CT/GT/IST" form
] Ongoing since previous follow-up	
Unknowr	1	

(EB	MT

ADDITIONAL CELL INFUSIONS

Did the pa	atient receive additional cell infusions (excluding a new HCT and CT) since the last follow-up?
🗌 Yes: 🛛	Is this cell infusion an allogeneic boost* ? 🔲 No 👘 Yes
	* An allogeneic boost is an infusion of cells from the same donor without conditioning, with no evidence of graft rejection.
	Date of the allogeneic boost: / _ / (YYYY/MM/DD)
ls	s this cell infusion an autologous boost? 🔲 No 👘 Yes
Unknov	Date of the autologous boost: / _ / _ (YYYY/MM/DD) wn
If this cell infu	usion is not a boost, attach the Cell Infusion (CI) sheet available in Appendix 6, completing as many

sheets as episodes of cell infusion that took place during this interval; then continue below.

Did the patient receive subsequent HCT/CT (either at your or another centre)?

No
Yes

If the patient had a subsequent HCT/CT, please, make sure that this subsequent treatment is registered using the appropriate treatment form before proceeding.



RELAPSE, PROGRESSION, RECURRENCE OF DISEASE OR SIGNIFICANT WORSENING (not relevant for Inborn errors)

	a relapse, progression, sease since last follow-			or significant worsening of organ f ethod)	unction related to the
🗌 No					
☐ Yes;	for every relapse, progi	ression, rec	currence, sigr	nificant worsening complete the questi	ons below
	Type: 🗌 Relapse / Re	ecurrence o	f disease		
	🔲 (Continuous)) progressio	on / Significa	nt worsening	
	Data of relanse/progra	ssion/roc	irroncolwor	sening: / / (YYYY/MM/	
	Extended dataset	ssionneci			
	In case of relapse or pr	ogression ((CML only)		
	Type of relapse: (select worst detected at t	this time poir	nt) □ Haema	atological; Disease status at relapse	Accelerated phase
				protic	Blast crisis
			Molecu		
			Unkno	wn	
	In case of relapse or p	rogression	(MPN only)		
	Type of relapse:			matological	
	(select worst detected at	this time poi		ecular	
			🔲 Unkr	nown	
	Malignant disorders o Type of relapse/pr		:		
	Medullary:	🗌 No	🗌 Yes	🔲 Unknown	
	Extramedullary:	🗌 No	🗌 Yes	Unknown	
	If the relapse/prog	ression was	s extramedul	lary or both medullary and extramedul	lary:
	Involvement at tim	ne of relaps	se/progressi	ion:	
	Skin:	🗌 No	☐ Yes	☐ Not evaluated	
	CNS: Testes/Ovaries:	🗌 No	🗌 Yes	☐ Not evaluated	
	Other:	🗌 No	Yes	☐ Not evaluated	
		🗌 No	Yes; spe	ecify:	

copy and fill-in this table as many times as necessary.

Unknown



Treatment Type	🗌 нст
----------------	-------

DISEASE STATUS

Disease specific

Disease status at this follow-up or at time of death*:

* Indicate the disease status at this follow-up or at time of death corresponding to indication diagnosis by selecting from the list provided in Appendix 1

PREGNANCY AFTER HCT

Has patient become pregnant or impregnated another person since last follow-up?

No; Extended dataset Was there an attempted pregnancy since last follow-up? □ No □ Yes □ Unknown			
Yes: Did the pregnancy result in a live birth?			
No; Date of spontaneous or induced termination: / _ / _ (YYYY/MM/DD) 🔲 Unknown			
Yes; Year of birth: (YYY) Month of birth: (MM) 🔲 Unknown			
Still pregnant at time of follow-up			
Unknown			
Extended dataset Conception method: Natural Assisted Unknown 			
Unknown			



Appendix 1

Best Response and Disease Status (Disease Specific)

Complete only one section with the main indication diagnosis for which HCT was given.

ACUTE LEUKAEMIAS	Go to page 37
CHRONIC LEUKAEMIAS	Go to page 37
PLASMA CELL NEOPLASMS (PCN)	Go to page 38
MPN, MDS, MDS / MPN OVERLAP SYNDROMES	Go to page 40
AUTOIMMUNE DISORDERS	Go to page 41
HAEMOGLOBINOPATHIES	Go to page 41
LYMPHOMAS	Go to page 42
SOLID TUMOURS	Go to page 42
BONE MARROW FAILURE SYNDROMES (BMF) including APLASTIC ANAEMIA (AA)	Go to page 42
OTHER DIAGNOSIS	Go to page 43
Inborn Errors	Go to page 44



Appendix 1

Best Response and Disease Status (Disease Specific)

Acute leukaemias (AML, PLN, Other)

,	·, · ····,			
Complete remission	(CR)			
Not in complete remi	ssion			
□ Not evaluated				
Unknown				
Proceed to next page for	Diseases Status section			
Chronic leukaemias (CM	L, CLL, PLL, Other)			
Chronic Myeloid Leukae	emia (CML):			
Chronic phase (CP);	Number: 1 st 2 nd	☐ 3 rd or	higher	Unknown
	Haematological remission	n: 🗌 No	🗌 Yes	🗌 Not evaluated 📋 Unknown
	Cytogenetic remission:	🗌 No	🗌 Yes	🗌 Not evaluated 📋 Unknown
Extended dataset				
In case of NO cytogenet Cytogenetic details :	<mark>tic remission</mark> t(9;22) positive metaphases	:	(%)	🔲 Not evaluated 🔲 Unknown
	t(9;22) positive cells detecte	d by FISH	:	(%) 🔲 Not evaluated 🔲 Unknown
	Molecular remission:	🗌 No	🗌 Yes	☐ Not evaluated ☐ Unknown
Extended dataset In case of NO molecula BCR::ABL1 variant all	r remission ele frequency (VAF):	_%	Unknown	
Accelerated phase; N	Number: 1 st 2 nd	3rd or	higher	Unknown
t(§	9;22) positive metaphases: _ 9;22) positive cells detected ele frequency (VAF):	by FISH: _		☐ Not evaluated ☐ Unknown _ (%) ☐ Not evaluated ☐ Unknown
Blast crisis; Number:	1 st 2 nd] 3 rd or hig	her 🗌 Ur	known
Extended dataset				
Cytogenetic details: t(§	9;22) positive metaphases: _		(%)	🔲 Not evaluated 🔲 Unknown
t(9	9;22) positive cells detected	by FISH: _		_ (%) 🔲 Not evaluated 🔲 Unknown
BCR::ABL1 variant alle	ele frequency (VAF):	_% 🔲	Unknown	
☐ Not evaluated				
Unknown				

Proceed to next page for Diseases Status section



Appendix 1

Best Response and Disease Status (Disease Specific)

Chronic Lymphocytic Leukaemia (CLL). Prolymphocytic Leukaemia (PLL) and other chronic leukaemias:

Complete remission (CR)		
Partial remission (PR)		
Progression: Resistant to last regimen	Sensitive to last regimen	Unknown
Stable disease (no change, no response/loss of r	response)	
☐ Relapse		
☐ Not evaluated		
Unknown		

Proceed to next page for Diseases Status section

Plasma cell neoplasms (PCN)

Complete remission (CR)	Number: 🗍 1st		
Stringent complete remission (sCR)			
Ury good partial remission (VGPR)	☐ 3rd or higher		
Partial remission (PR)	Unknown		
Relapse	_		
Progression			
Stable disease (no change, no response/loss of response)			
Not evaluated			
Unknown			

Extended dataset

Immunoglobulin-related (AL) Amyloidosis only

Organ response during this follow-up period:

Heart	□ Response □ No change □ Progression □ Not involved □ Not evaluated	Unknown
Kidney	Response No change Progression Not involved Not evaluated	Unknown
Liver	Response No change Progression Not involved Not evaluated	Unknown
Peripheral nervous system	☐ Response ☐ No change ☐ Progression ☐ Not involved ☐ Not evaluated	

Proceed to next page for Diseases Status section



Treatment Type	HCT
neument type	1101

Appendix 1 Best Response and Disease Status (Disease Specific) continued
Complete only for PCN Disease Status
Was the patient on dialysis during this follow-up period? No Yes; Started in this follow-up period: Start date:// (YYYY/MM/DD) Unknown Ongoing since previous follow-up Did dialysis stop? No Yes; End date:// (YYYY/MM/DD) Unknown Unknown
Complete only for AL, CLL and PCN Disease Status Leukaemias (AL, CLL) and PCN (complete only for patient in CR or sCR) Minimal residual disease (MRD): Positive Increasing (>1log10 change) Stable (<1log10 change) Decreasing (>1log10 change) Unknown Negative
 Not evaluated Unknown Date MRD status evaluated:/ (YYYY/MM/DD)
Date MRD status evaluated: $/ / / / / / / / / / / / / / / / / / / $



Treatment Type	НСТ
----------------	-----

Appendix 1
Best Response and Disease Status (Disease Specific)
continued

Myeloproliferative neoplasms (MPN), Myelodysplastic neoplasms (MDS), MDS/MPN overlap syndromes

Complete remission (CR)	Number: 1st
	☐ 2nd
	Grd or higher
	Unknown
Improvement but no CR	
Primary refractory phase (no change)	
□ Relapse	Number: 1st
	☐ 2nd
	☐ 3rd or higher
	Unknown
Progression/Worsening	
☐ Not evaluated	
Unknown	



Treatment Type	П	НСТ
----------------	---	-----

Appendix 1

Best Response and Disease Status (Disease Specific)

continued

Autoimmune disorders

□ No evidence of disease
Improved
Unchanged
U Worse
Not evaluated

Haemoglobinopathies

<u>Thalassaemia:</u>

Complete only for Thalassen	nia Best Response
Transfusion independent	Date of last transfusion: / _ / (YYYY/MM/DD) Unknown (after HCT)
Transfusions required;	Date of first transfusion://(YYYY/MM/DD) Unknown (after HCT)
☐ Not evaluated	
Unknown	

Complete or	nly for Thala	assemia Diseas	se Status
	ing for fille		

Patient requires transfusions during follow-up period:			
No No			
Yes; Return to transfusion dependence after HCT or transfusion free period;	Date of first transfusion: //(<i>YYYY/MM/DD</i>) Unknown (after HCT or transfusion free period)		
Ongoing transfusion dependence since previous assessment			
Number of units: Image: Im			
Did transfusions stop? 🔲 No			
☐ Yes; Date of la	st transfusion: / _ / (YYYY/MM/DD) 🔲 Unknown		
¦ 🗌 Unknown			
Unknown			



Treatment Type	HCT
----------------	-----

Appendix 1

Best Response and Disease Status (Disease Specific)

continued

Lymphomas

Chemorefractory relapse or progression, including primary refractory disease			
Complete remission (CR):	Confirmed	Unconfirmed (CRU*)	🔲 Unknown
Partial remission (PR)			
Stable disease (no change, no response/loss of response)			
Untreated relapse (from a previous CR) or progression (from a previous PR)			
Not evaluated			
Unknown			

* CRU: Complete response with persistent scan abnormalities of unknown significance

Solid tumours

Complete remission (CR): Confirmed Unconfirmed Unknown			
First partial remission			
Partial remission (PR)			
Progressive disease			
🗌 Relapse: 🔄 Resistant 📋 Sensitive 📋 Unknown			
Stable disease (no change, no response/loss of response)			
Not evaluated			
Unknown			

Bone marrow failures (incl. AA)

Complete remission (CR)
Partial remission (PR)
Haematological improvement (HI); <i>NIH partial response</i>
Stable disease (no change, no response/loss of response)
Relapse / Progression
Not evaluated
Unknown

	/ failures (incl. AA) Disease Status	ì
Did transfusions stop during	Patient was never transfusion dependent	i
the follow-up period?	□ No	I I
1	Yes; Did the patient return to transfusion dependency afterwards?	Ľ
	□ No	i
1 1 1	Yes; First transfusion date://(YYYY/MM/DD) Unknown (after transfusion free period)	1
	Unknown	i
1	Unknown	i
1		1



Appendix 1	L
------------	---

Best Response and Disease Status (Disease Specific)

continued

Haemoglobinopathies

Sickle cell disease:

Complete only for Sickle cell disease Best Response

No return of sickling episodes	
Return of sickling episodes;	Date of first episode: / _ / (YYYY/MM/DD) Unknown (after HCT)
Not evaluated	
🔲 Unknown	

Complete only for Sickle cell disease Disease Status

Sickling episodes occur during follow-up period:

÷.		
 	□ No	
 	Yes; First return of sickling episodes after Date of first episode : / _ / _ (YYYY/MM/DD) □ Unknown HCT (after HCT)	ı
	Ongoing presence of sickling episodes	
	Number of SCD episodes: Unknown (during follow-up)	

Other diagnosis

No evidence of disease
No response
U Worse
□ Not evaluated

(EBMT	

EBMT Centre Identification Code (CIC): ____ Hospital Unique Patient Number (UPN): _____ Patient Number in EBMT Registry: _____ Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 1

Disease Status Inborn errors only

ended dataset	
atient height at this follow-up: _	cm 🔲 Not evaluated 📋 Unknown
atient weight at this follow-up: _	kg 🔲 Not evaluated 🔲 Unknown
Alternativ	hool/work school/adapted work not able to attend work/school
(Only for Inhorn array of Imme	ty)
(Only for Inborn errors of Immu nmune profiling done during this Test date: / / (YYY	
nmune profiling done during this	
nmune profiling done during this Test date://(YYY Cell type and test results	// <i>MM/DD</i>) Unknown
mmune profiling done during this Test date://(YYY	//MM/DD) Unknown Units (for CD4 and CD8, select unit)
nmune profiling done during this Test date: //// Cell type and test results CD3 T-cells:	r/MM/DD) □ Unknown □ Not evaluated □ Unknown Cells/μl
nmune profiling done during this Test date: //// Cell type and test results CD3 T-cells:	<pre>//MM/DD) □ Unknown Units (for CD4 and CD8, select unit) □ Not evaluated □ Unknown Cells/µl □ Not evaluated □ Unknown</pre>
nmune profiling done during this Test date: //(YYY) Cell type and test results CD3 T-cells:	<pre>//MM/DD) □ Unknown Units (for CD4 and CD8, select unit) □ Not evaluated □ Unknown □ Not evaluated □ Unknown Cells/μl □ Not evaluated □ Unknown Cells/μl</pre>
nmune profiling done during this Test date: // (YYY) Cell type and test results CD3 T-cells:	<pre>//MM/DD) □ Unknown //MM/DD) □ Unknown Units (for CD4 and CD8, select unit) □ Not evaluated □ Unknown Cells/μl □ Not evaluated □ Unknown Cells/μl</pre>
mmune profiling done during this Test date: //(YYY) Cell type and test results CD3 T-cells:	//MM/DD) □ Unknown Units (for CD4 and CD8, select unit) □ Not evaluated □ Unknown Cells/μl □ Not evaluated □ Unknown Cells/μl
nmune profiling done during this Test date: / _ / _ (YYY) Cell type and test results CD3 T-cells:	//MM/DD) □ Unknown Units (for CD4 and CD8, select unit) □ Not evaluated □ Unknown Cells/μl □ Not evaluated □ Unknown Cells/μl
mmune profiling done during this Test date: / _ / _ (YYY) Cell type and test results CD3 T-cells:	//MM/DD) □ Unknown Units (for CD4 and CD8, select unit) □ Not evaluated □ Unknown Cells/μl □ Not evaluated □ Unknown Cells/μl



Treatment Type		HCT
----------------	--	-----

Appendix 1

Disease Status (Only for Inborn errorrs of immunity)

Extended dataset

Select the immunomodulatory treatments the patient received in the 3 months before the follow-up. Only report treatments administered in the 3 months before this follow-up. Do not report treatments for GvHD or other HCT/CT related complications, only for the underlying disease ☐ No treatment given ☐ IVIG SCIG Steroids (>0.5 mg/kg/day prednison equivalent) Cyclosporine A Tacrolimus Sirolimus Ruxolitinib Baricitinib Other JAK-inhibitor, specify: _ Leniolisib Abatacept Anakinra Canakinumab Etoposide Interferon gamma Etanercept Infliximab Vedolizumab Dupilumab Emapalumab PEG-ADA Other drug; specify: ____

Unknown



Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 1 Disease Status

Inborn errors of Immunity only

Extended dataset

Comorbidities during this follow-up period

Only for Inborn Errors of Immunity

Indicate in the table below if the comorbidities de novo, resolved, improved, stabilised or worsened during this follow-up period. No No Inflammatory bowel Crohn's disease or □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo ulcerative colitis disease Not evaluated SLE, RA, polymyositis, No No mixed CTD or Rheumatologic □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo polymyalgia rheumatica Not evaluated Serum creatinine > 2 No No mg/dL or >177 µmol/L, Renal: □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo moderate/severe on dialysis, or prior renal transplantation Not evaluated Chronic hepatitis, 🗌 No bilirubin between Upper Limit Normal □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo Hepatic: mild (ULN) and 1.5 x ULN, or AST/ALT between Not evaluated ULN and 2.5 × ULN Liver cirrhosis, □ No bilirubin greater than Hepatic: 1.5 × ULN, or □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo moderate/severe AST/ALT greater than Not evaluated 2.5 × ULN Bronchiectasis, No No interstitial Chronic lung pneumonitis, GLILD, □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo disease oxygen dependency, structural lung disease Not evaluated (e.g. pneumatoceles) No No Leukaemia, Pre-HCT lymphoma, Yes: In remission Stable disease Relapsed Not evaluated malignancy myelodysplastic syndrome (MDS) Not evaluated No No Weight <3rd percentile ☐ Yes: ☐ Resolved ☐ Improved ☐ Stabilised ☐ Worsened ☐ De novo Failure to thrive or requirement for (par)enteral feeding Not evaluated No No Any infection requiring therapy in the Active infection at Resolved Improved Stabilised Worsened Yes: HCT immediate pre HCT period Not evaluated No No I.e. splenomegaly, Lymphoproliferation organ specific □ Yes: □ Resolved □ Improved □ Stabilised □ Worsened □ De novo lymphoproliferation 🔲 Not evaluated



EBMT Centre Identification Code (CIC): ____ Hospital Unique Patient Number (UPN): _____ Patient Number in EBMT Registry: _____

Treatment Type	🗌 нст
.	

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 1

Disease Status

Inborn errors only

Extended dataset

Comorbidities during this follow-up period

Only for Inborn Errors of Immunity

Indicate in the table below if the comorbidities de novo, resolved, improved, stabilised or worsened during this follow-up period.

	Pre-HCT organ impairment	Infectious or non-infectious (including neurologic)	 No Yes: Resolved Not evaluated 	Improved	Stabilised	U Worsened
	Autoimmunity/ autoinflammation	Pre HCT/CT (includes patients in remission but on immunomodulatory treatment within 3 months before HCT/CT)	 No Yes: Resolved Not evaluated 	Improved	Stabilised	U Worsened
Va	as the patient admitted to ICU during this follow-up period? 🗌 No			☐ Yes	Unknown	



Treatment Type

Appendix 2

-- Pathogens as per EBMT Registry database --

*<u>As defined by the IDSA</u> (Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45)

Bacterial infections

Gram-positive:

- · Clostridioides difficile
- · Enterococcus faecalis (vancomycin-susceptible)
- · Enterococcus faecalis (vancomycin-resistant)
- · Enterococcus faecium (vancomycin-susceptible)
- \cdot Enterococcus faecium (vancomycin-resistant)
- Listeria monocytogenes
- · Nocardia spp (specify)
- · Staphylococcus aureus MSSA (methicillin-susceptible)
- · Staphylococcus aureus MRSA (methicillin-resistant) vancomycin-susceptible
- · Staphylococcus aureus MRSA (methicillin-resistant) vancomycin not tested
- · Staphylococcus aureus MRSA and VISA (vancomycin-intermediate, MIC 4-8 µg/ml)
- \cdot Staphylococcus aureus MRSA and VRSA (vancomycin-resistant, MIC \geq 16 µg/ml)
- \cdot Staphylococcus coagulase-negative spp (at least two positive blood cultures)
- · Streptococcus pneumoniae
- · Streptococcus viridans
- · Streptococcus other spp (specify)
- · Gram-positive bacteria other spp (specify)

Gram-negative:

- · Acinetobacter baumannii
- · Campylobacter jejuni
- \cdot Citrobacter freundii
- · Enterobacter cloacae
- · Enterobacter other spp (specify)
- · Escherichia coli
- · Haemophilus influenzae
- · Helicobacter pylori
- · Klebsiella aerogenes (carbapenem-susceptible)
- · Klebsiella pneumoniae (carbapenem-susceptible)
- \cdot Klebsiella (any species) (carbapenem-resistant) (specify)
- \cdot Legionella pneumophila
- Morganella morganii
- · Neisseria gonorrhoeae
- · Neisseria meningitidis
- Proteus vulgaris
- \cdot Providencia spp
- · Pseudomonas aeruginosa (carbapenem-susceptible)
- · Pseudomonas aeruginosa (carbapenem-resistant)
- · Salmonella spp (specify)
- · Serratia marcescens
- · Shigella spp
- · Stenotrophomonas maltophilia
- Treponema pallidum
- · Gram-negative bacteria other spp (specify)

Other bacteria:

- · Chlamydia spp
- · Chlamydophila
- · Mycobacterium other spp (specify)
- · Mycobacterium tuberculosis
- \cdot Mycoplasma pneumoniae
- · Rickettsia spp
- \cdot Bacteria other (specify)

2025-06-23

Viral infections: · Adenovirus

· Gastrointestinal viruses:

o Norovirus

o Rotavirus

o HAV

o HBV

o HCV

o HEV

· Herpes group:

o CMV

o EBV

o HHV6

o HHV7

o HHV8

Human papilloma viruses (HPV)

o Other polyomavirus (specify)

o Respiratory virus other (specify)

o HS

o VZ

· Parvovirus

o BK

o JC

· Polyomaviruses:

o Merkel cell

· Respiratory viruses:

o Enterovirus

o Influenza A

o Influenza B

o Rhinovirus

o RSV

o Parainfluenza

o SARS-CoV-2

· Viruses other (specify)

o Human coronavirus

o Metapneumovirus

· HIV

· Hepatotropic viruses:



Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Appendix 2

-- Pathogens as per EBMT Registry database -- continued

*<u>As defined by the IDSA</u> (Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45)

Fungal infections:

Yeasts:

- Candida albicans
- · Candida auris
- · Candida other (specify)
- · Cryptococcus neoformans
- · Trichosporon (specify)
- Pneumocytis jiroveci
- \cdot Yeasts other (specify)

Moulds:

- · Aspergillus flavus
- · Aspergillus fumigatus
- · Aspergillus other spp (specify)
- · Aspergillus terreus
- · Fusarium other spp (specify)
- \cdot Fusarium solani
- · Lomentospora prolificans (formerly Scedosporium prolificans)
- · Order Mucorales (specify)
- · Dematiaceous fungi (Phaeohyphomycosis) (specify)
- · Scedosporium spp (specify)
- \cdot Moulds other spp (specify)
- · Mould infection diagnosed based on positive galactomannan only, without
- microbiological confirmation
- Blastomyces spp
- · Histoplasma spp (specify)
- · Coccidioides spp
- · Paracoccidioides spp

Parasitic infections:


- Protozoa:
- · Babesia spp (specify)
- · Cryptosporidium
- · Giardia spp
- · Leishmania spp (specify)
- · Plasmodium spp (specify)
- Toxoplasma gondii
- · Trypanosoma cruzi
- · Protozoa other spp (specify)

Helminths:

- · Strongyloides stercoralis
- · Other helminths



Treatment Type	
----------------	--





	Appendix 4 Is Complications CTCAE term No Reporting	g Required
Non-infectious complications Allergic reaction All laboratory abnormalities All types of pain Alopecia Blurred vision Diarrhoea (enteropathy) Dry mouth Dyspepsia Dysphagia Edema Sore throat Esophageal stenosis Fatigue Vertigo Flashes Weight loss	 Infectious complications Minor ophthalmologic bacterial infections External otitis treated topically Otitis media treated with oral antibiotics Isolated lip herpes simplex Bacterial tonsillitis or pharyngitis treated orally Laryngitis without viral identification managed at home by inhalations or without any intervention URTI without viral/bacterial identification managed at home Bilateral cervical lymph node enlargement concurrent with URTI that resolved without specific treatment, together with the resolution of URTI Local superficial wound infection resolved under topical antibiotics (incl. impetigo) Minor skin bacterial infections Minor fungal skin infection Diaper rash treated with local antifungals Candidal balanitis treated topically 	 Vaginal candidiasis treated topically or with a single oral dose Asymptomatic bacteriuria due to a pathogen not multi-resistant Single low urinary tract infection treated orally without need for hospitalisation Phlebitis following peripheral intravascular infusion that resolved after intravascular removal without treatment with antibiotics Any isolate that is considered part of the normal flora of the place (oral cavity, vagina, skin, stools) except if it carries an antimicrobial resistance that has clinical implications (induce isolation precautions or a pathogen-directed therapy) Positive culture without clinical implications
	Appendix 5	

-- Intravascular catheter-related infections --

CVC infections:

· Catheter colonization · Tunnel infection

Phlebitis
 Pocket infection

Exit site infection
 Bloodstream infection



Patient Number in EBMT Registry: ______

Treatment Type 🔲 HCT

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Appendix 6 Cell Infusion Sheet Chronological number of CI episode for this patient: Date of the first infusion (within this episode): _ _ / _ / _ (YYYY/MM/DD) Not applicable for Inborn Errors Number of infusions within this episode (10 weeks): (Count only infusions that are part of the same regimen and given for the same indication.) Source of cells: Allogeneic ☐ Autologous Type of cells: Lymphocytes (DLI) ☐ Mesenchymal ☐ Fibroblasts ☐ Dendritic cells □ NK cells ☐ Regulatory T-cells ☐ Gamma/delta cells Virus-specifc T-cells; specify virus: Other; specify: ____ Not applicable for Inborn Errors Disease status at time of this cell infusion*: * Indicate the disease status corresponding to indication diagnosis by selecting from the list provided in Appendix 1 Indication: Poor graft function (check all that apply) ☐ Infection prophylaxis □ Planned/protocol Other; specify: _____ ☐ Prophylactic Treatment of acute GvHD Treatment of chronic GvHD ☐ Treatment PTLD, EBV lymphoma Treatment for primary disease ☐ Mixed chimaerism Loss/decreased donor chimaerism Treatment of viral infection other than EBV Acute GvHD -- maximum grade (after this infusion episode but before any subsequent cell infusion/HCT/CT): □ 0 (none) \Box 1 □ 2 Date Acute GvHD onset after cell infusion: ____/ __/ (YYYY/MM/DD) □ 3 Unknown Π4 □ Present but grade unknown